General Milvexian fails to reduce cardiovascular events after acute coronary syndromeBy Healthcare Propulsion StaffAugust 29, 20260 Milvexian did not reduce major adverse cardiovascular events compared with placebo after a recent acute coronary syndrome and there was…
